GHK-Cu + BPC-157 Blend
A single-vial pairing of GHK-Cu and BPC-157 that combines skin and collagen repair with connective-tissue and gut healing.
The GHK-Cu + BPC-157 blend places two well-characterized repair peptides in one vial: GHK-Cu, the copper-bound tripeptide with the strongest cosmetic skin-repair record in the catalog, and BPC-157, the gastric-derived pentadecapeptide studied for connective-tissue and GI repair. The two components target largely non-overlapping tissue, GHK-Cu at the skin surface and dermis, BPC-157 in deeper structural and visceral tissue, which is why clinics and community stacks pair them rather than double up. The pairing is mechanistically coherent and widely used, but there is no controlled trial on the fixed blend, and BPC-157's human evidence is thin even on its own.
Class
Fixed-ratio blend: tripeptide-copper complex (GHK-Cu) plus synthetic pentadecapeptide (BPC-157)
Half-life
GHK-Cu: tissue-dependent, ~12 h detectable; BPC-157: short (minutes after IV)
Routes
Subcutaneous injection, Topical (GHK-Cu component)
Category
Healing & Recovery
Researched benefits
What it's studied for
Complementary two-compartment repair coverage
GHK-Cu's documented action concentrates in skin, collagen, and dermal remodeling, while BPC-157's concentrates in tendon, ligament, gut lining, and vascular tissue. Combining them widens tissue coverage in a single injection rather than stacking the same effect.
Collagen synthesis and dermal remodeling
GHK-Cu delivers copper to crosslinking enzymes such as lysyl oxidase and modulates gene expression tied to skin regeneration; the Pickart-Margolina 2015 review maps effects across more than 4,000 genes. This anchors the blend's skin-quality and post-procedure healing profile.
Angiogenesis-driven connective-tissue repair
BPC-157 promotes angiogenesis at injury sites and shows tissue-repair signals across tendon, ligament, and vascular tissue in a large rodent dataset. This provides the structural-recovery half of the blend.
Gut-lining and GI repair signal
BPC-157 is derived from a protective protein in gastric juice and shows consistent gut-lining repair effects in animal models, extending the blend's coverage to visceral tissue that GHK-Cu does not address.
Single-injection repair stack for post-procedure recovery
Users and clinics reach for the blend to combine skin quality and post-procedure healing from the GHK-Cu half with tendon, ligament, and gut recovery from the BPC-157 half. These outcomes are plausible from each component's pharmacology but rest on distributed practice experience and component-level trials rather than a controlled blend study.
Mechanism
How it works
The blend is best understood as two distinct repair mechanisms delivered together, not a single unified pathway. GHK-Cu is a copper-bound tripeptide (glycine-histidine-lysine plus a copper ion) that acts largely at the skin surface and dermis. It delivers copper to enzymes such as lysyl oxidase that crosslink collagen, and it modulates gene expression tied to skin regeneration and wound healing, with effects mapped across more than 4,000 genes in the Pickart-Margolina 2015 review.
BPC-157 is a 15-amino-acid gastric-derived fragment that works mostly in deeper structural and visceral tissue. It promotes angiogenesis at injury sites and shows tissue-repair signals across tendon, ligament, gut lining, and vascular tissue in animal models. The two molecules differ substantially in mass and chemistry, GHK-Cu at 403.9 Da and copper-bound, BPC-157 at 1419.53 Da, so they behave differently in reconstituted solution.
The rationale for pairing them is division of labor: GHK-Cu covers skin and collagen, BPC-157 covers connective tissue and gut, so the combination broadens repair coverage rather than amplifying a single effect. This complementary pharmacology is why clinics and the research-peptide community put the two in the same vial once it was clear they target non-overlapping tissue.
The missing piece is not the mechanism story, which is coherent for each component, but a fixed-blend outcome trial. There is no RCT on the GHK-Cu plus BPC-157 vial, and BPC-157's own human evidence is limited. Labeled-ratio durability in solution is also formulation-, storage-, and time-dependent, and is source-specific rather than independently established.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Component-derived (practice pattern)
- Dose
- Source-specific; blend ratios vary by vendor
- Frequency
- Not standardized
- Timing
- Not standardized
- Duration
- Not standardized
- Route
- Subcutaneous injection (or topical GHK-Cu)
There is no FDA-approved dosing framework for either component or the blend, and no fixed-dose trial defines a regimen. Community route and schedule claims should be treated as practice patterns, not label instructions, and typically follow the individual GHK-Cu and BPC-157 protocols.
- No fixed-blend dosing has been established; regimens are inferred from the separate GHK-Cu and BPC-157 protocols.
- Blend ratios, formulations, and reconstitution vary by source, so labeled ratios may not hold in solution over time.
- GHK-Cu and BPC-157 differ in mass, chemistry, and stability, which affects how a reconstituted blend behaves.
- Research-vendor products are not FDA-reviewed; vial identity and sterility are part of the risk.
Evidence
Research & clinical studies (2)
Regenerative and Protective Actions of the GHK-Cu Peptide (Pickart-Margolina review)
Maps GHK-Cu gene-expression effects across skin-regeneration pathways, describing modulation of more than 4,000 genes tied to collagen synthesis and dermal remodeling.
Mayfield review of injectable peptides in sports medicine
Assessed both GHK-Cu and BPC-157 within the injectable-peptide landscape and concluded the preclinical signal is real but human clinical evidence is insufficient, with distinct tissue targets for each molecule.
Combinations
Stacking & blends
GHK-Cu + BPC-157 Blend
Combine surface skin and collagen repair with deeper connective-tissue and gut healing in one injection
The two peptides target largely non-overlapping tissue, so pairing them widens repair coverage rather than duplicating a single effect.
KLOW Blend
Broader multi-tissue healing coverage
Extends the GHK-Cu + BPC-157 pairing with TB-500 and KPV to add further connective-tissue repair and anti-inflammatory action.
BPC-157 + TB-500 Blend
Connective-tissue and systemic repair
An alternative BPC-based repair blend that pairs BPC-157 with TB-500 instead of GHK-Cu, emphasizing structural recovery over skin remodeling.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- No approved therapeutic use; not for use outside research contexts
- Prohibited for WADA-tested athletes due to the BPC-157 component (S0)
Reported side effects are generally mild and consistent with the individual components. Long-term human safety for injectable use of either component is not fully characterized, and research-vial identity and sterility are part of the risk.
FAQ
GHK-Cu + BPC-157 Blend — common questions
What is the GHK-Cu / BPC-157 blend?
A combination of two repair-focused peptides in a single vial: GHK-Cu, a copper-bound tripeptide with a strong cosmetic skin-repair record, and BPC-157, a synthetic gastric-derived pentadecapeptide studied for connective-tissue and GI repair. GHK-Cu works mostly on skin, collagen, and dermal remodeling, while BPC-157 works mostly on tendon, ligament, gut lining, and vascular tissue.
What does the blend do?
It targets two repair compartments at once. GHK-Cu delivers copper to collagen-crosslinking enzymes and modulates skin-regeneration gene expression, while BPC-157 promotes angiogenesis and tissue repair at injury sites in animal models. The combined claims rest on GHK-Cu's topical clinical evidence plus BPC-157's preclinical and community evidence, not a direct blend RCT.
Does the blend heal injuries faster than either peptide alone?
This is unverified. It is plausible from the non-overlapping mechanisms, but no controlled study compares the blend against either component or placebo. The claim is component inference plus practice pattern, not a measured blend outcome.
How is the blend typically administered?
Research and clinic formulations vary, and there is no FDA-approved dosing framework for either component or the blend. Community route and schedule claims should be treated as practice patterns rather than label instructions.
What are the side effects?
Reported effects are generally mild and consistent with the components: injection-site soreness, occasional transient blue-green pigmentation at the site from the copper in GHK-Cu, and the generally clean tolerability BPC-157 reports. Long-term human safety for injectable use is not fully characterized.
Is the blend FDA approved?
No. Neither component is FDA-approved for any indication, and the blend has no approved use. On April 22, 2026 the FDA removed both injectable GHK-Cu and BPC-157 from 503A category 2. BPC-157 is prohibited under WADA S0 for tested athletes; GHK-Cu is not, and topical GHK-Cu remains legal under cosmetic regulation.
Do blend vials hold their labeled ratio in solution?
This is unverified. GHK-Cu (403.9 Da, copper-bound) and BPC-157 (1419.53 Da) differ in mass, chemistry, and stability, so they behave differently once reconstituted. Labeled-ratio durability depends on formulation, storage, and time after reconstitution, and is source-specific.
